{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:47:31Z","timestamp":1789915651479,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.3816\/clm.2009.n.085","type":"journal-article","created":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T02:02:24Z","timestamp":1262743344000},"page":"430-435","source":"Crossref","is-referenced-by-count":25,"title":["Serum Levels of Total-RANKL in Multiple Myeloma"],"prefix":"10.3816","volume":"9","author":[{"given":"Christian","family":"Jakob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Goerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Sterz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Heider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"K\u00fchnhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Ziefle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Kleeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Mieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"von Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.n.085_bib1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"10.3816\/CLM.2009.n.085_bib2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/sj.thj.6200313","article-title":"Consequences of interactions between the bone marrow stroma and myeloma","volume":"4","author":"Epstein","year":"2003","journal-title":"Hematol J"},{"key":"10.3816\/CLM.2009.n.085_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcmd.2004.04.012","article-title":"Myeloma cells (5TMM) and their interactions with the marrow microenvironment","volume":"33","author":"Menu","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"10.3816\/CLM.2009.n.085_bib4","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"10.3816\/CLM.2009.n.085_bib5","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","article-title":"RANK ligand and osteoprotegerin in myeloma bone disease","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.085_bib6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1634\/theoncologist.2009-0003","article-title":"Myeloma bone disease: Recent advances in biology, diagnosis and treatment","volume":"14","author":"Sezer","year":"2009","journal-title":"Oncologist"},{"key":"10.3816\/CLM.2009.n.085_bib7","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1006\/bbrc.2000.3379","article-title":"Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines","volume":"275","author":"Nakashima","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3816\/CLM.2009.n.085_bib8","doi-asserted-by":"crossref","first-page":"13613","DOI":"10.1074\/jbc.274.19.13613","article-title":"Evidence for a role of a tumor necrosis factoralpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival","volume":"274","author":"Lum","year":"1999","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2009.n.085_bib9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1006\/bbrc.2000.2314","article-title":"Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF\/TRANCE that induces osteoclast formation","volume":"269","author":"Nagai","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.3816\/CLM.2009.n.085_bib10","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3816\/CLM.2009.n.085_bib11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.coph.2004.03.011","article-title":"Evidence of a role for RANKL in the development of myeloma bone disease","volume":"4","author":"De Leenheer","year":"2004","journal-title":"Curr Opin Pharmacol"},{"key":"10.3816\/CLM.2009.n.085_bib12","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.085_bib13","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.085_bib14","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1023\/A:1027362507683","article-title":"Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells","volume":"20","author":"Okada","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"10.3816\/CLM.2009.n.085_bib15","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.085_bib16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.085_bib17","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.n.085_bib18","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1517\/14728222.12.11.1377","article-title":"Novel targets for myeloma bone disease","volume":"12","author":"Roodman","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"10.3816\/CLM.2009.n.085_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2141.1997.8672495.x","article-title":"Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG)","volume":"96","author":"Abildgaard","year":"1997","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.085_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1365-2141.2000.01960.x","article-title":"Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients","volume":"109","author":"Fonseca","year":"2000","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.085_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0609.2002.00505.x","article-title":"Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline(Dpd)] in MGUS and multiple myeloma","volume":"69","author":"Jakob","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.n.085_bib22","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.085_bib23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.085_bib24","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V98.7.2269","article-title":"Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease","volume":"98","author":"Seidel","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.085_bib25","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.leu.2403429","article-title":"Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age-and sex-matched healthy controls","volume":"18","author":"Corso","year":"2004","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.085_bib26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2141.2005.05518.x","article-title":"Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma","volume":"129","author":"Depil","year":"2005","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.085_bib27","first-page":"454","article-title":"Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients","volume":"53","author":"Kraj","year":"2005","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.3816\/CLM.2009.n.085_bib28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.085_bib29","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.085_bib30","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V96.4.1505","article-title":"High incidence of chromosome 13 deletion in multiple myeloma detected by multi-probe interphase FISH","volume":"96","author":"Shaughnessy","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.085_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2141.2003.04417.x","article-title":"Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma","volume":"122","author":"Liebisch","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.085_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc [Ser A]"},{"key":"10.3816\/CLM.2009.n.085_bib33","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.ejca.2005.11.034","article-title":"Bone markers in multiple myeloma","volume":"42","author":"Heider","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.3816\/CLM.2009.n.085_bib34","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/leu.2008.159","article-title":"Incorporation of the bone marker carboxyterminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma","volume":"22","author":"Jakob","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.085_bib35","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3324\/haematol.10943","article-title":"Serum levels of OPG, RANKL and RANKL\/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations","volume":"92","author":"Goranova-Marinova","year":"2007","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.n.085_bib36","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/00365510701432509","article-title":"Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high-sensitivity C-reactive protein","volume":"67","author":"Sennels","year":"2007","journal-title":"Scand J Clin Lab Invest"},{"key":"10.3816\/CLM.2009.n.085_bib37","first-page":"268","article-title":"The OPG\/RANKL\/RANK system in metabolic bone diseases","volume":"4","author":"Hofbauer","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.3816\/CLM.2009.n.085_bib38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.humimm.2008.01.006","article-title":"The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients","volume":"69","author":"Sch\u00fctt","year":"2008","journal-title":"Hum Immunol"},{"key":"10.3816\/CLM.2009.n.085_bib39","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.leu.2403423","article-title":"Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL\/osteoprotegerin ratio in patients with multiple myeloma","volume":"18","author":"Terpos","year":"2004","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.085_bib40","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"issue":"suppl 5","key":"10.3816\/CLM.2009.n.085_bib41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3816\/CLM.2007.s.024","article-title":"Current standards for first-line therapy of multiple myeloma","volume":"7","author":"Jagannath","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLM.2009.n.085_bib42","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3816\/CLM.2008.n.027","article-title":"Progress in multiple myeloma","volume":"8","author":"Jagannath","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLM.2009.n.085_bib43","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/sj.leu.2404843","article-title":"The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma","volume":"21","author":"Terpos","year":"2007","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.085_bib44","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/leu.2008.235","article-title":"The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed\/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis","volume":"22","author":"Terpos","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.085_bib45","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","article-title":"Bortezomib inhibits human osteoclastogenesis","volume":"21","author":"von Metzler","year":"2007","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.n.085_bib46","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2007.06665.x","article-title":"Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK","volume":"138","author":"Hecht","year":"2007","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.n.085_bib47","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.yexcr.2007.10.021","article-title":"Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)","volume":"314","author":"Hecht","year":"2008","journal-title":"Exp Cell Res"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T13:41:11Z","timestamp":1739713271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011700348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1557919011700348"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.n.085","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}